Newly FDA approved Motiva Implants offer a safer alternative for breast enhancement procedures, demonstrating notably reduced rates of complications in comparison to existing breast implant options, while also delivering improved outcomes and visual appeal.
Log in to view the full article
Newly FDA approved Motiva Implants offer a safer alternative for breast enhancement procedures, demonstrating notably reduced rates of complications in comparison to existing breast implant options, while also delivering improved outcomes and visual appeal.
“With the FDA approval last week, we are experiencing high demand for Motiva Implants — both from surgeons and patients,” said Juan José Chacón-Quirós, Founder and Chief Executive Officer of Establishment Labs. “The FDA approval came as we were attending the annual conference of the American Society of Plastic Surgeons. The response was overwhelming, and our team has already talked to more than 400 plastic surgeons post announcement. Since approval, we have already doubled our team to 25 sales reps across the United States, and our story of real innovation, backed by science and data, is resonating strongly.”
The recent FDA approval of Motiva SmoothSilk Ergonomix and Motiva SmoothSilk Round breast implants for initial and reconstructive breast enhancement has paved the way for groundbreaking surgeries in the United States. Two board-certified plastic surgeons have taken the lead in performing these procedures: M. Bradley Calobrace, M.D., and Caroline A. Glicksman, M.D. These medical professionals have become the pioneers in utilizing the newly sanctioned implants for breast augmentation operations within the country, marking a significant advancement in the field of plastic surgery.
“I have many patients that have been waiting a long time for Motiva approval, in some cases, for years,” said Dr. Calobrace. “I was delighted to perform one of the first Motiva breast augmentations in the United States. The innovation in these devices not only enhances aesthetics outcomes, but also significantly lowers the rates of the complications we see with other devices. Motiva implants are a game changer.”
The SmoothSilk surface technology incorporated in Motiva Implants has been shown to minimize post-operative inflammation and enhance biocompatibility. By addressing these concerns associated with current breast implant options, Motiva Implants' advanced safety features represent a significant step forward in meeting the need for safer breast augmentation alternatives, helping to mitigate the risks linked to the procedure.
In addition, the two implant styles available enhance the aesthetic appearance and results of breast augmentation procedures. The Motiva SmoothSilk Ergonomix is engineered to mimic natural breast tissue in feel, behavior, and movement. It features a distinctive ergonomic form that adjusts to body movements, maintaining a teardrop shape while standing and a round shape when reclined. In contrast, the Motiva SmoothSilk Round Implants offer enhanced upper breast volume and suppleness, consistently retaining a full round shape regardless of body position.
“The plastic surgery community has waited more than a decade to offer breast augmentation patients in the United States something truly new,” said Dr. Glicksman, Medical Director of the Motiva U.S. IDE Study and a clinical trial investigator. “Now, we can confidently offer our patients implants that have consistently shown low complication rates and high patient satisfaction.”
